These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21426051)

  • 21. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 26. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.
    Graham G; Gueorguieva I; Dickens K
    Comput Methods Programs Biomed; 2005 Jun; 78(3):237-49. PubMed ID: 15899308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-based approaches to in silico pharmacology.
    Vidal D; Garcia-Serna R; Mestres J
    Methods Mol Biol; 2011; 672():489-502. PubMed ID: 20838981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical formulations for discovery and toxicology: physicochemical challenges.
    Neervannan S
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing need for bioanalysis during drug development.
    Srinivas NR
    Biomed Chromatogr; 2008 Mar; 22(3):235-43. PubMed ID: 17939165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
    Reife RA
    Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
    Karlsson MO; Anehall T; Friberg LE; Henningsson A; Kloft C; Sandström M; Xie R
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):206-11. PubMed ID: 15733216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice.
    Clark GT; Haynes JJ; Bayliss MA; Burrows L
    Bioanalysis; 2010 Aug; 2(8):1477-88. PubMed ID: 21083348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can positron emission tomography facilitate paediatric drug development?
    Zimmer L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications of physiologically based absorption models in drug discovery and development.
    Parrott N; Lave T
    Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.